The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

ASND FINANCIAL STATEMENTS

Ascendis Pharma AS — balance sheet, income statement and cash flow trends

ASNDAscendis Pharma AS

🇺🇸 USA · US · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
-500 M0500 M202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue867.5 M €Gross Profit764.9 M € · 88%Operating Income-6.9 M € · -1%Pre-tax Income-167.8 M € · -19%Net Income506.6 M € · 58%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue867.5 M €+135.3%
Gross Profit764.9 M €+143.2%
Operating Income-6.9 M €—
EBITDA12.4 M €—
Net Income506.6 M €—

Peer Comparison· Biotechnology

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
ASND135.3%88.2%1.4%58.4%
Industry median4.1%84.0%-105.8%-125.7%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
01 B2 B202120222023202420252026

Capital Structure

Q1 2026
Total Assets2 B
  • Equity488.5 M €24%
  • Current Liabilities1.1 B €56%
  • Long-term Liabilities388.9 M €19%

Key Figures

YoY change
Total Assets2 B €+88.9%
Total Liabilities1.5 B €+21.2%
Total Equity488.5 M €—
Cash & ST Investments573.4 M €+10.7%
Total Debt897.6 M €+5.9%
Net Debt324.2 M €-1.6%

Peer Comparison· Biotechnology

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
ASND1.00183.8%26.2124.4%
Industry median5.9010.9%1.1570.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-600 M-400 M-200 M0202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
020 M40 M60 M57.6 M €Operating-14.6 M €Investing16.8 M €Financing59.8 M €Net Change

Key Figures

YoY change
Operating Cash Flow57.6 M €—
Capital Expenditures15.5 M €+719.3%
Free Cash Flow42.1 M €—
Dividends Paid——

Peer Comparison· Biotechnology

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
ASND6.6%4.9%1.8%11.4%
Industry median-88.0%-90.9%1.9%81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ASND

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. This content is for informational purposes only and is not investment advice.